Utilisation du lénalidomide dans les syndromes myélodysplasiques del(5q)ADES, L.Correspondances en onco-hématologie. 2014, Vol 9, Num 2, pp 76-80, issn 1954-4820, 5 p.Article

Advances in the 5q- syndromeBOULTWOOD, Jacqueline; PELLAGATTI, Andrea; MCKENZIE, Andrew N. J et al.Blood. 2010, Vol 116, Num 26, pp 5803-5811, issn 0006-4971, 9 p.Article

Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletionDEFINA, Marzia; RONDONI, Michela; GOZZETTI, Alessandro et al.British journal of haematology. 2010, Vol 148, Num 3, pp 483-484, issn 0007-1048, 2 p.Article

Erythropoïèse des syndromes myélodysplasiques: cas du syndrome 5qVINCENT, Laure.Hématologie (Montrouge). 2010, Vol 16, pp 17-20, issn 1264-7527, 4 p., SUP3Conference Paper

Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survivalCZIBERE, Akos; BRUNS, Ingmar; JUNGE, Bärbel et al.Haematologica (Roma). 2009, Vol 94, Num 10, pp 1453-1455, issn 0390-6078, 3 p.Article

Van-den Berghe's 5q-syndrome in 2008MOHAMEDALI, Azim; MUFTI, Ghulam J.British journal of haematology. 2009, Vol 144, Num 2, pp 157-168, issn 0007-1048, 12 p.Article

Syndrome 5q- : caractéristiques hématologiques, physiopathologie et traitement = 5q-syndrome : characteristics, physiopathology and treatmentKELAIDI, Charikleia; DA ROCHA, Ana Oliveira; FENAUX, Pierre et al.Hématologie (Montrouge). 2008, Vol 14, Num 4, pp 259-269, issn 1264-7527, 11 p.Article

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndromePELLAGATTI, Andrea; CAZZOLA, Mario; WAINSCOAT, James S et al.British journal of haematology. 2011, Vol 155, Num 2, pp 272-274, issn 0007-1048, 3 p.Article

Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic SyndromesGIAGOUNIDIS, Aristoteles A. N.Seminars in hematology. 2012, Vol 49, Num 4, pp 312-322, issn 0037-1963, 11 p.Article

Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q-syndromeLOPEZ-VILLAR, O; GARCIA, J. L; HERNANDEZ-RIVAS, J. M et al.Leukemia. 2009, Vol 23, Num 4, pp 664-672, issn 0887-6924, 9 p.Article

5q-syndrome : New Treatment Strategy of the Myelodysplastic SyndromesBOULTWOOD, Jacqueline; PELLAGATTI, Andrea; WAINSCOAT, James S et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 22, pp 3180-3183, issn 1381-6128, 4 p.Article

Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des MyelodysplasiesADES, Lionel; LE BRAS, Fabien; TURLURE, Pascal et al.Haematologica (Roma). 2012, Vol 97, Num 2, pp 213-218, issn 0390-6078, 6 p.Article

Patients âgés atteints de syndrome myélodysplasique avec anomalie 5q- traités par lénalidomide: à propos de deux observations avec évolution défavorable = Elderly patients with myelodysplastic syndrome with del 5q receiving lenalidomide: two case reports with poor prognosisREIBEL, Florence; DEBORD, Camille; BOUHADIBA, Samir et al.Annales de biologie clinique (Paris). 2010, Vol 68, Num 2, pp 248-253, issn 0003-3898, 6 p.Article

Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormalityHARADA, Hironori; WATANABE, Mitsumasa; TANIWAKI, Masafumi et al.International journal of hematology. 2009, Vol 90, Num 3, pp 353-360, issn 0925-5710, 8 p.Article

Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomideGÖHRING, G; LANGE, K; SCHLEGELBERGER, B et al.Leukemia. 2012, Vol 26, Num 2, pp 356-358, issn 0887-6924, 3 p.Article

Identification of RPS14 as a 5q^-syndrome gene by RNA interference screenEBERT, Benjamin L; PRETZ, Jennifer; GOLUB, Todd R et al.Nature (London). 2008, Vol 451, Num 7176, pp 335-339, issn 0028-0836, 5 p.Article

Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomideECLACHE, Virginie; DA ROCHA, Anna; LE ROUX, Génevieve et al.Haematologica (Roma). 2008, Vol 93, Num 2, pp 315-316, issn 0390-6078, 2 p.Article

Blood consult: treating del(5q) myelodysplastic syndromesMUKHERJEE, Sudipto; TIU, Ramon V; SEKERES, Mikkael A et al.Blood. 2012, Vol 119, Num 2, pp 342-344, issn 0006-4971, 3 p.Article

NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotypeAMMATUNA, Emanuele; PANETTA, Paola; AGIRRE, Xabier et al.Haematologica (Roma). 2011, Vol 96, Num 5, pp 784-785, issn 0390-6078, 2 p.Article

Different boundaries characterize isolated and non-isolated 5q deletions in myelodysplastic syndromes and acute myeloid leukemiasNOFRINI, Valeria; LA STARZA, Roberta; CRESCENZI, Barbara et al.Haematologica (Roma). 2012, Vol 97, Num 5, pp 792-794, issn 0390-6078, 3 p.Article

SPARC is dispensable for murine hematopoiesis, despite its suspected pathophysiological role in 5q-myelodysplastic syndromeSIVA, K; JAAKO, P; MIHARADA, K et al.Leukemia. 2012, Vol 26, Num 11, pp 2416-2419, issn 0887-6924, 4 p.Article

Molecular Dissection of the 5q Deletion in Myelodysplastic SyndromeEBERT, Benjamin L.Seminars in oncology. 2011, Vol 38, Num 5, pp 621-626, issn 0093-7754, 6 p.Article

Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomideGÖHRING, Gudrun; GIAGOUNIDIS, Aristoteles; BÜSCHE, Guntram et al.Haematologica (Roma). 2011, Vol 96, Num 2, pp 319-322, issn 0390-6078, 4 p.Article

The JAK2 V617F mutation identifies a subgroup of MD5 patients with isolated deletion 5q and a proliferative bone marrowINGRAM, W; LEA, N. C; ARNO, M. J et al.Leukemia. 2006, Vol 20, Num 7, pp 1319-1321, issn 0887-6924, 3 p.Article

The molecular signature of MDS stem cells supports a stem-cell origin of 5q-myelodysplastic syndromesNILSSON, Lars; EDEN, Patrik; SAMUELSSON, Jan et al.Blood. 2007, Vol 110, Num 8, pp 3005-3014, issn 0006-4971, 10 p.Article